04 April 2022, London – Qinecsa Solutions announced the acquisition of MyMeds&Me Limited (MMM). Qinecsa, a leading provider of pharmacovigilance services and technologies to the global pharmaceutical industry.
UK-headquartered, MyMeds&Me capture safety data directly from patients, healthcare professionals and Pharma teams across multiple intake channels through its global SaaS platform, Reportum®. MMM has a broad, well-established, and global client base, which includes some of the world’s leading pharmaceutical companies.
The combined, digital-first organisation will provide a best-in-class pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Embracing a digital-first approach will enable Qinecsa to be the foremost provider of pharmacovigilance services, leveraging Reportum for the capture and management of relevant data, supported by the highest calibre of medical and scientific staff.
This strategy will also accelerate the development of the Reportum platform to enhance its inherent capabilities and provide seamless integrations with other solutions in the technology landscape, both pre- and post-approval. Together, Qinecsa and MMM will provide the industry with a dynamic offering that encompasses a compelling technology roadmap and world-class services to meet customer portfolio and business requirements.
“The acquisition of MMM will give a further boost to the high-quality service offering we are delivering to our clients, which include some of the world’s largest and most innovative pharmaceutical companies, with the support and investment of SCP.” said CEO of Qinecsa. “The acquisition aligns with Qinecsa strategy to secure M&A transactions that grow the technology-enabled platform and broaden the client-focused service offering.”
“MyMeds&Me is proud to be joining the Qinecsa family, providing us with a framework to expand our high-quality technology offering. With the industry’s ever greater focus on patient engagement, the deployment of innovative technology combined with complementary services from Qinecsa will enable our customers to revolutionise their pharmacovigilance strategy and optimise the safe use of their medicines.”
“Qinecsa overall strategy remains at the forefront of specialist service provision is supported by this acquisition,” said CEO. “We look forward to supporting MMM in building innovative technology to navigate the rapidly evolving landscape of pharmacovigilance. This state-of-the-art software will support the industry in accommodating higher volumes of data and heightened patient awareness regarding drug safety.”
About Qinecsa Solutions UK
Qinecsa are specialists in technology led end-to-end pharmacovigilance solutions. We are trusted, global partners bringing together best-in-class technology and scientific expertise to connect life science companies to the right safety solutions. Through our unique insight into the challenges of pharmacovigilance, we have created industry-leading, end-to-end solutions for capturing, managing, and evaluating drug safety data, more efficiently and accurately. Working with life science companies we drive progress to continue protecting lives.
About MyMeds&Me
MyMeds&Me was founded in 2012 by Pharma industry experts. The company provides an end-to-end pharmacovigilance solution, Reportum®, to standardise adverse event and product quality data capture across all intake routes and accelerate safety insights. Reportum is a proven, scalable drug safety platform, in high volume use by Pharma & CROs around the world.
